5 Key Takeaways

• 1

  In the REPLENISH trial, 41% of patients receiving secukinumab achieved sustained remission at 52 weeks compared to 20% receiving placebo.

• 2

  The trial enrolled 381 patients aged 50 or older with relapsed polymyalgia rheumatica across 148 sites in 28 countries.

• 3

  Complete sustained remission occurred in 28% of the secukinumab 300 mg group, 25% in the 150 mg group, and 5% in the placebo group.

• 4

  Patients receiving secukinumab had lower annual cumulative glucocorticoid exposure, with doses 20% to 23% lower than the placebo group.

• 5

  Serious adverse events occurred in 14-16% of patients in the secukinumab groups, with fungal infections reported more frequently than in the placebo group.